HER2 Cell-Based Assay for Mutation Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to functionally assess the impact of HER2 mutations on protein activity and their response to inhibitors, limiting personalized treatment strategies for HER2-positive breast cancers.
Innovation Solution
A cell-based assay method involving the preparation of cDNA encoding HER2 variants, transfection into assay cells with a JNK reporter construct, exposure to HER3 ligand, and treatment with HER2 inhibitors to determine sensitivity and activity, using luciferase activity as a measure of signal change.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If next generation sequencing is used to identify DNA sequences of tumors, then the mutational landscape can be established, but functional information of the identified mutations cannot be obtained
Solution Approach 1:
The patent introduces an intermediary cell-based assay system that bridges the gap between DNA sequence identification and functional information. The assay uses reporter genes (luciferase, GFP) as mediators to translate mutation effects into measurable signals, thereby recovering the functional information that was lost after sequencing.
Solution Approach 2:
The patent replaces traditional biochemical assays with a cellular system that integrates genetic reporting. Instead of direct biochemical measurement, the system uses cellular expression mechanisms and optical detection (luciferase bioluminescence, GFP fluorescence) to assess mutation function, substituting mechanical/biochemical methods with optical detection.
2Loss of information
If cell-based assays are developed to measure HER2 activity, then functional information can be obtained, but the complexity of the assay system increases
Solution Approach 1:
The patent creates a universal cell-based assay platform that can evaluate multiple HER2 variants and test multiple inhibitors within the same system. The standardized reporter cell line serves multiple functions: measuring baseline HER2 activity, assessing variant effects, and evaluating inhibitor sensitivity, thereby managing complexity through multi-functionality.
Solution Approach 2:
The patent manages assay complexity by changing detectable parameters rather than physical system complexity. Using optical parameters (light emission from luciferase, fluorescence from GFP) provides a simple readout that transforms complex cellular responses into measurable signals, reducing the perceived complexity of the assay.
3Measurement precision
If personalized treatment strategies are implemented based on mutational landscapes, then treatment precision can be improved, but additional functional testing requirements increase the complexity
Solution Approach 1:
The patent performs preliminary functional characterization of HER2 variants using the cell-based assay before clinical treatment decisions are made. By pre-assessing which variants are sensitive to specific inhibitors through this standardized assay, the system eliminates the need for complex sequential testing during treatment planning, thereby reducing overall testing complexity while maintaining high treatment precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for precise determination of HER2 variant sensitivity to inhibitors and activity, providing valuable guidelines for tailored treatment approaches based on mutational landscapes.
Implementation Method 1
using luciferase activity as a measure of signal change
Data Source
AI summary
The present invention relates to cell-based assays involving HER2. The assays use assay cells that are transfected with cassettes containing the HER2 gene of interest and measure the effect of mutations on the activity of HER2, and on their response to inhibitors.